PYPD - Earnings announcements

The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three months and full year ended December 31, 2025. Recent Corporate Highlights: Advancing Towa

PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness with Successful Completion of IMOH GMP Inspection Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 202

PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question o

Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Obesity and Diabetes Market Successful Warrant Exercise Significantly Strengthened Balance Sheet with Cash Runway into 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and six

PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery patients with large incisions. The double-blind trial of 798 patients achieved statistical significance across all endpoints, demonstrating a 38% reduction in the primary composite endpoint and a remarkable 58% reduction in SSI rates from 9.5% to 3.8% compared to standard care alone. These results position D-PLEX100 among the most effective prophylactic interventions for this indication, addressing a significant unmet medical need that costs the U.S. healthcare system up t

D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the rate of surgical site infections ("SSI") in patients treated with D-PLEX100 arm versus standard of care ("SoC") arm (p<0.005).The Company expects to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in early 2026, with a Marketing Authorization Application ("MAA") in the E.U. to follow shortly thereafter.PolyPid will conduct a conference call and webcast at 8:30 A.M. ET today. PETACH TIKVA, Israel,

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025Time:8:30 AM Easte

PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2025. Recent Corporate Highligh

PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of ma

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enrolled more than 700 Patients to Date; Enrollment Completion Expected in March 2025, with Top-Line Results Anticipated in Second Quarter of 2025 Company Completed Private Placement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrants Expected to Extend Cash Runway Beyond Potential NDA Approval Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate

PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not p

Last Patient Enrolled for Planned Unblinded Interim Analysis in Ongoing SHIELD II Phase 3 Trial of D-PLEX100  Unblinded Interim Analysis Outcome Expected Later this Quarter SHIELD II Enrollment Completion Expected in December 2024 with Top-Line Results Anticipated in First Quarter of 2025 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial res

PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 13, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a questi

Approximately 320 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up, Which is Expected in Fourth Quarter of 2024; Top-Line Results Anticipated in First Quarter of 2025 Recent Successful Financing of Up to $14 Million Extends Company's Cash Runway into Second Quarter of 2025, Beyond the Anticipated Timing for SHIELD II Top-line Results, Assuming Warrants are Fully Exercised Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:

PETACH TIKVA, Israel, July 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Approximately 50 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2024. Recent Cor

PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of m

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company's Cash Runway Through Late Third Quarter 2024 and Beyond Expected Timing of Unblinded Interim Analysis; Potential Additional $19 Million if Warrants are Exercised to Fund PolyPid to the Start of a Planned New Dr

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to a

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of D-PLEX100 Successful Completion of Good Manufacturing Practice Audit of Company's Manufacturing Facility Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine m

PETACH TIKVA, Israel, Nov. 01, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of

Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and Israel Expected to be Opened by End of Current Quarter Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and six months ended June 30, 2023. Recent Corporate Highlight

PETACH TIKVA, Israel, July 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 9, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of

PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 10, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of ma

Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient Recruitment in Q2 2023 into Ongoing SHIELD II Trial, which will be Enriched with Approximately 550 Additional Patients to Complete Clinical Testing for Potential NDA Top-line Results from SHIELD II Trial Anticipated mid-2024 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported fi

PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a

Company Intends to Meet with U.S. and EU Regulatory Authorities to Discuss Data from SHIELD I Phase 3 Study and Regulatory Pathway for D-PLEX100 in First Quarter of 2023 Implemented a Cost Reduction Plan, Including a 20% Decrease in Headcount Across All Departments Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2022. Recent Corporate Highlights: Announced top-line results from SHIELD I (Surg

PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a questio

Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus Royalties on Net SalesIndependent Data Safety Monitoring Board Recommended Concluding Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Following Enrollment of the Minimum Number of Targeted PatientsConcluded Enrollment in Phase 3 SHIELD I TrialTop-line Results from the Phase 3 SHIELD I Trial Anticipated by End of Q3 2022Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 10, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aimin

PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 10, 2022. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide an update on business operations. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a uni

• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days • Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 • Conference Call Scheduled for Today at 8:30 a.m. ET PETACH TIKVA, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced today that following the independent Data Safety Monitoring Board (DSMB) review of unblinded efficacy data from the first 750 enrolled patients in the SHIELD I Phase 3 study of D-PLEX100 for the prevention of surgical site infections

•  Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently •  Recruitment Progressing as Planned with Approximately 900 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery •  Extended Cash Runway into the Second Quarter of 2023 with $15 million Non-Dilutive Secured Term Loan Facility •  Strengthened Executive Management Team •  Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provide

PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information: Date: Wednesday, May 11, 2022Time:8:30 AM Eastern TimeUnited States:+1 877-870-9135Israel:+972 1809 213-985International:+44 (0) 2071 928338Confe

• FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up• Recruitment Progressing as Planned with Approximately 680 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery. Expect to Reach 750 Enrolled Patients by End of First Quarter 2022 and Have Unblinded Interim Analysis During the Second Quarter of 2022• Recently Completed Planned 500-Patient Blinded Sample Size Reassessment of SHIELD I Supports the Continuation of the Trial• Conference Call Scheduled for Today at 8:30 AM ET   PETACH TIKVA, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("P

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information: Date: Wednesday, February 9, 2022Ti

Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Following FDA Agreement that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal Surgery, Company Intends to Target Higher End of Patient Enrollment Range in SHIELD I to Leverage Key Clinical, Commercial and Financial Benefits Company's Cash Runway Extends to Year-End 2022, ahead of Prior Forecast of Q2 2022 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Compan

PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its third quarter 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, November 10, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information: Date: Wednesday, November 10, 2021Time:8:30

•  Recruitment Progressing as Planned with Over 300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery •  FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal Surgery •  Brain Tumors Selected as the Initial Indication for Company's OncoPLEX Intra-tumoral Cancer Therapy Program •  Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today

PETAH TIKVA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its second quarter 2021 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 11, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information: Date: Wednesday, August 11, 2021Time:8:30 AM Eastern TimeUnited States:+1 877 870 9135Israel:+972 18